✦ LIBER ✦

350 Radical prostatectomy with long neoadjuvant hormonal therapy can be effective for high-risk localized prostate cancer patients

✍ Scribed by M. Kato; T. Tsuzuki; R. Hattori; M. Gotoh

Book ID: 119624282
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 35 KB
Volume: 11
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(12)60347-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Circulating prostate-specific antigen mR

Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy

✍ Ogawa, Osamu ;Iinuma, Masanori ;Sato, Kazunari ;Sasaki, Ryusei ;Shimoda, Naotake 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 186 KB

Re: Multicenter Phase II Study of Combin

Re: Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy before Radical Prostatectomy for Patients with High Risk Localized Prostate Cancer

✍ P. Beuzeboc 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Neoadjuvant docetaxel followed by radica

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report

✍ William K Oh; Daniel J George; Donald S Kaufman; Keri Moss; Matthew R Smith; Jer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 569 KB

688 NEOADJUVANT COMBINATION THERAPY OF D

688 NEOADJUVANT COMBINATION THERAPY OF DOCETAXELAND COMPLETE ANDROGEN DEPRIVATION FOR LOCALIZED HIGH RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY

✍ M.K. Thalaott; U. Treiber; T. Maurer; M. Heck; M. Eiber; B. Reimer; K. Herkommer 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Cancer-specific mortality after radiatio

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer

✍ Henry K. Tsai; Ming-Hui Chen; David G. McLeod; Peter R. Carroll; Jerome P. Richi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 2 views

## Abstract ## BACKGROUND. The presence of multiple determinants of aggressive cancer biology may impact prostate cancer‐specific mortality (PCSM) rates compared with fewer factors. The authors estimated PCSM after radiation therapy with short‐course androgen suppression therapy (RT+AST) or radica

Phase II trial of neoadjuvant docetaxel

Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer

✍ Jacqueline Vuky; Christopher Porter; Christina Isacson; Matthew Vaughan; Paul Ko 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract ## BACKGROUND: Prostate cancer trials investigating neoadjuvant hormonal therapy, followed by surgery, have demonstrated that elimination of all tumor cells from the primary site is rare. The authors report a phase 2 trial assessing the efficacy and toxicity of docetaxel and gefitinib